• Explore /
  • Poster
  • / Study EV-103: New cohorts testing enfortumab vedotin alone or in combination with pembrolizumab in muscle invasive urothelial cancer.

Study EV-103: New cohorts testing enfortumab vedotin alone or in combination with pembrolizumab in muscle invasive urothelial cancer.

Abstract Poster

Authors

Christopher Hoimes

Christopher J. Hoimes

University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH

Christopher J. Hoimes , Jonathan E. Rosenberg , Daniel Peter Petrylak , Anne-Sophie Carret , Carolyn Sasse , Marya F. Chaney , Thomas W. Flaig

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers

Track

Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03288545

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr TPS595)

Abstract #

TPS595

Poster Bd #

N13

Abstract Disclosures

Similar Posters

First Author: Nataliya Mar

First Author: Jonathan E. Rosenberg

First Author: Jonathan E. Rosenberg

First Author: Thomas W. Flaig